|

Adjuvant therapy Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: Standard of Care

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

  • Philogen S.p.A.1
  • Fudan University1
  • Criterium, Inc.1

Indications

  • Cancer3
  • Melanoma Stage IIID1
  • Melanoma Stage IIIC1
  • Melanoma Stage IIIB1
  • Nasopharyngeal Cancinoma (NPC)1

Other1 trial

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
Phase 2

Phoenix, Arizona1 trial

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

Mayo Clinic Hospital

Phase 3

Tucson, Arizona1 trial

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

University of Arizona Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.